Silo Pharma EBITDA vs. Revenue

SILO Stock  USD 1.00  0.10  11.11%   
Based on the key profitability measurements obtained from Silo Pharma's financial statements, Silo Pharma may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Silo Pharma's ability to earn profits and add value for shareholders.
For Silo Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Silo Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Silo Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Silo Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Silo Pharma over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
Please note, there is a significant difference between Silo Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Silo Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silo Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Silo Pharma Revenue vs. EBITDA Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Silo Pharma's current stock value. Our valuation model uses many indicators to compare Silo Pharma value to that of its competitors to determine the firm's financial worth.
Silo Pharma is currently regarded as top stock in ebitda category among its peers. It is rated below average in revenue category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Silo Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Silo Pharma's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Silo Revenue vs. EBITDA

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Silo Pharma

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(3.86 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Silo Pharma

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
72.1 K
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Silo Revenue vs Competition

Silo Pharma is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 27.04 Billion. Silo Pharma adds roughly 72,102 in revenue claiming only tiny portion of equities under Health Care industry.

Silo Pharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Silo Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Silo Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Silo Pharma's change in net profit over the period of time. It can combine multiple indicators of Silo Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey. Silo Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2 people.

Silo Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Silo Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Silo Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Silo Pharma's important profitability drivers and their relationship over time.

Use Silo Pharma in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Silo Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Silo Pharma will appreciate offsetting losses from the drop in the long position's value.

Silo Pharma Pair Trading

Silo Pharma Pair Trading Analysis

The ability to find closely correlated positions to Silo Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Silo Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Silo Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Silo Pharma to buy it.
The correlation of Silo Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Silo Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Silo Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Silo Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Silo Pharma position

In addition to having Silo Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run World Allocation Funds Thematic Idea Now

World Allocation Funds
World Allocation Funds Theme
Funds or Etfs investing in stocks, bonds, and cash of domestic markets as well as in markets of Canada, Japan, and Europe. The World Allocation Funds theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize World Allocation Funds Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Silo OTC Stock

To fully project Silo Pharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Silo Pharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Silo Pharma's income statement, its balance sheet, and the statement of cash flows.
Potential Silo Pharma investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Silo Pharma investors may work on each financial statement separately, they are all related. The changes in Silo Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Silo Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.